Clinical Trials on Stage I Skin Cancer in Austria

Total 689 results

Hoffmann-La Roche

Terminated

A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer

Triple Negative Breast Cancer | Advanced Ovarian Cancer

United Kingdom, United States, Australia, Denmark, Canada
Eli Lilly and Company
Loxo Oncology, Inc.

Recruiting

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)

Breast Cancer

United States, Spain, Korea, Republic of, China, France, Germany, Japan, Belgium, Italy, Australia, United Kingdom, Canada, Singapore
Sanofi
Cancer International Research Group (CIRG)

Completed

Docetaxel in Breast Cancer

Breast Cancer

France, Hong Kong, Korea, Republic of, Russian Federation, Spain, United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Cyprus, Czech Republic, Egypt, Estonia, ... and more
Sanofi

Active, not recruiting

A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)

Malignant Melanoma | Squamous Cell Carcinoma of Skin

Germany, Spain, France, Chile, United States, Australia, Italy
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
AstraZeneca
Quintiles; University of Tubingen - Germany

Completed

International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study (BREAKOUT)

Breast Cancer

United States, Bulgaria, Italy, Korea, Republic of, Russian Federation, Spain, Turkey, Canada, Poland, Australia, Hungary, Taiwan, Japan, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer (BOLERO-3)

Metastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast Cancer

China, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); Breast International Group

Active, not recruiting

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (TEXT)

Breast Cancer

United States, Australia, Switzerland, Italy, Canada, Belgium, Peru, United Kingdom, Egypt, New Zealand, Slovenia, South Africa, Sweden, Hungary, India, Germany, Brazil
AstraZeneca

Active, not recruiting

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC (SELECT-1)

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

United States, Canada, France, Italy, Spain, United Kingdom, Belgium, Poland, Brazil, Germany, Hungary, Peru, Russian Federation, Turkey, Australia, Chile, Austria, Netherlands, Portugal, Israel, Mexico, Romania, Sweden, Ukraine, Bulgaria, Argenti...
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Melanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCC

Korea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
Queen Mary University of London

Completed

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer (IBIS II)

Breast Cancer

Ireland, United Kingdom, Switzerland, Australia, Belgium, Chile, Denmark, Finland, Germany, Hungary, Italy, Malta, Portugal, Turkey
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Dermatofibrosarcoma Protuberans | Adult Angiosarcoma | Adult Epithelioid Sarcoma | Adult Extraskeletal Osteosarcoma | Adult Fibrosarcoma | Adult Leiomyosarcoma and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico
Eli Lilly and Company

Active, not recruiting

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

Breast Cancer

Canada, Germany, Australia, Japan, United States, Taiwan, Belgium, New Zealand, Italy, Israel, Spain, France, Netherlands, Mexico, Turkey, United Kingdom, Korea, Republic of, Austria, Puerto Rico, Sweden, Russian Federation, Greece, Slovaki...
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

Breast Cancer

United States, Canada, Australia, Ireland
Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
Eisai Inc.
Merck Sharp & Dohme LLC

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC) (ENHANCE-1)

Breast Neoplasm

United States
University of Rostock
German Breast Group; German Cancer Aid

Active, not recruiting

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery (INSEMA)

Breast Cancer

Austria, Germany
Novartis Pharmaceuticals

Completed

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1)

Breast Cancer

United States, France, Spain, United Kingdom, Austria, Germany, Taiwan, Australia, Italy, Israel, Russian Federation, Korea, Republic of, Hong Kong, Thailand, Canada, Hungary, Japan, Lebanon, Belgium, Bulgaria, Greece, Argentina, Peru, Czech... and more
ETOP IBCSG Partners Foundation

Completed

Bone Density and Bone Loss in Postmenopausal Women With Breast Cancer Receiving Treatment in Clinical Trial IBCSG-1-98

Breast Cancer | Osteoporosis

France, Italy, Switzerland, Australia, Peru, Spain, New Zealand, South Africa
Stemline Therapeutics, Inc.

Active, not recruiting

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD)

Breast Cancer

United States, Spain, Israel, Italy, Korea, Republic of, Australia, United Kingdom, Hungary, France, Portugal, Belgium, Ireland, Argentina, Austria, Canada, Denmark, Greece
Daiichi Sankyo, Inc.
AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...

Active, not recruiting

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

HER2-Positive Primary Breast Cancer | Residual Invasive Breast Cancer

United States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
Arcus Biosciences, Inc.

Recruiting

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers (ARC-25)

Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Bladder Cancer | Advanced Cancer | Non-Small Cell Lung Cancer (NSCLC) | Advanced Malignancies | Renal Cell Carcinoma (RCC) | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC) | Gastroesophageal-junction...

United States, Australia
Bristol-Myers Squibb
Janssen Biotech, Inc.

Completed

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

Advanced Cancer

United States, Switzerland, France, Puerto Rico, Italy, Germany, Australia, Canada, Spain
Bristol-Myers Squibb

Completed

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL)

Breast Cancer

China, Russian Federation, United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Hong Kong, Ireland, Korea, Republic of, Mexico, Netherlands, Poland, Portuga... and more
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica
Alliance Foundation Trials, LLC.
Pfizer; Breast International Group; NSABP Foundation Inc; Austrian Breast & Colorectal... and other collaborators

Active, not recruiting

PALbociclib CoLlaborative Adjuvant Study (PALLAS)

Breast Cancer

United States, Spain, Italy, Ireland, United Kingdom, Australia, Germany, Japan, Portugal, Taiwan, Canada, Israel, Netherlands, Switzerland, Belgium, Austria, Hungary, Korea, Republic of, Mexico, Poland, Sweden
GlaxoSmithKline

Active, not recruiting

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST)

Neoplasms, Breast

United States, Argentina, France, Netherlands, Finland, Spain, Israel, Poland, Romania, Mexico, Canada, Belgium, Germany, Hungary, Portugal, United Kingdom, Ireland, Australia, Italy, Brazil, Japan, Austria, Russian Federation, South... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Prognostic Study of Sentinel Lymph Node and Bone Marrow Metastases in Women With Stage I or Stage IIA Breast Cancer

Breast Cancer

United States, Ireland, Australia
BeiGene

Recruiting

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast Cancer | Small Cell Lung Cancer | Gastric Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumor | Endometrial Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive Breast Cancer

United States, Australia
NGM Biopharmaceuticals, Inc
Merck Sharp & Dohme LLC

Recruiting

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Non-small Cell Lung Cancer | Colorectal Carcinoma | Bladder Urothelial Cancer | Endocervical...

United States
National Cancer Institute (NCI)

Active, not recruiting

Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Lynch Syndrome | Colon Mucinous Adenocarcinoma | Colon Signet Ring Cell Adenocarcinoma | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7

United States, Canada, Puerto Rico, Peru, South Africa
Eli Lilly and Company

Completed

Paclitaxel With or Without Gemcitabine in Treating Women With Advanced Breast Cancer

Breast Cancer

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Advanced or Metastatic Breast Cancer

United States, Taiwan, Japan, China, Canada, Korea, Republic of, Israel, Argentina, Australia, Brazil, Mexico, United Kingdom
US Oncology Research
Sanofi

Completed

Adj TC + Herceptin Early Stage Breast Cancer

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)

Breast Cancer

United States, China, Belgium, Canada, France, Italy, Taiwan, United Kingdom, Hungary, Australia, Spain, Germany, Singapore, Austria, Japan, Israel, Russian Federation, Korea, Republic of, Thailand, Slovakia, South Africa, Switzer... and more
AstraZeneca

Recruiting

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292)

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Spain, Denmark, United States, Korea, Republic of, Germany, Belgium, Vietnam, United Kingdom, France, Japan, Canada, China, India, Malaysia, Taiwan, Thailand, Australia, Turkey, Argentina, Brazil, Poland, Sweden, Italy
Gilead Sciences
Alliance Foundation Trials, LLC.; NSABP Foundation Inc

Recruiting

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63) (ASCENT-05)

Triple Negative Breast Cancer

United States
Queen Mary University of London
Cancer Research UK

Completed

Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ (IBIS-II DCIS)

Breast Cancer

France, Switzerland, Ireland, United Kingdom, Italy, Australia, Austria, Belgium, Chile, Germany, Hungary, Malta, Sweden, Turkey
Odonate Therapeutics, Inc.

Terminated

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA)

Breast Cancer

Korea, Republic of, United States, Spain, Canada, Singapore, Taiwan, Australia, Belgium, Thailand, Hungary, Germany, United Kingdom, France, Ukraine, Austria, Czechia, Italy, Poland, Russian Federation
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Breast Cancer

United States, France, Czechia, Italy, Korea, Republic of, Australia, Belgium, Brazil, Canada, Germany, Guatemala, Hong Kong, Hungary, Panama, Peru, Poland, Spain, Taiwan, United Kingdom, Colombia, Bosnia and Herzegovina, Chile, El... and more
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Locally Advanced or Metastatic Breast Cancer

France, Belgium, United States, Korea, Republic of, Taiwan, Brazil, China, Italy, Argentina, Jordan, Mexico, Germany, Portugal, Spain, Thailand, United Kingdom, Kenya, Turkey, Hungary, Colombia, India, Oman, Saudi Arabia, Poland, Uganda, United... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Canada, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
Novartis Pharmaceuticals

Completed

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (FACE)

Breast Cancer

China, United States, Belgium, Germany, Italy, Austria, Japan, Australia, Canada, Sweden, Switzerland, United Kingdom, Spain, Denmark, France, Ireland, Israel, Netherlands, Korea, Republic of, Norway
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

China, United States, Italy, Spain, United Kingdom, Korea, Republic of, Canada, Germany, Poland, Belgium, Japan, Vietnam, Bulgaria, France, Brazil, India, Malaysia, Taiwan, Thailand, Hungary, Australia, Austria, Turkey, Hong Kong, Switz... and more
Janssen Research & Development, LLC

Completed

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer

United States, Belgium, Spain, Germany, Sweden, Australia, United Kingdom
Pierre Fabre Medicament

Completed

Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer

Breast Cancer | Metastases

France, Ukraine, United Kingdom, Germany, Taiwan, Spain, Belarus, Belgium, Portugal, South Africa, Russian Federation, Austria, Italy, Argentina
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121)

Breast Cancer

Canada, Belgium, Korea, Republic of, United States, China, Taiwan, Mexico, Brazil, Argentina, Australia, Italy, Spain, Turkey, Thailand, United Kingdom, Poland, South Africa
Bristol-Myers Squibb

Completed

Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice

Melanoma | Lung Cancer

United States, Australia, Austria, Belgium, Czechia, France, Germany, Hungary, Italy, Poland, Puerto Rico, Spain, Switzerland, United Kingdom

Clinical Trials on Stage I Skin Cancer in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations